Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

A Study of Retifanlimab After Chemoradiation in People With Anal Cancer

NCT07927998 (PACER) is a recruiting, single-arm phase 2 MSK trial (estimated enrollment 25) of retifanlimab after definitive chemoradiation in people with anal squamous cell carcinoma who remain Signatera-positive, with the rate of ctDNA clearance at 12 weeks as the primary endpoint.

Memorial Sloan Kettering Cancer Center